FDA Remains Focused On Cosmetics Carrying Drug Claims – OCAC Director
This article was originally published in The Rose Sheet
At the American Conference Institute’s Legal, Regulatory and Compliance Forum on Cosmetics, FDA Office of Cosmetics and Colors Director Linda Katz discussed her division’s priorities for the year. On the enforcement front, OCAC will continue to focus on cosmetic products marketed with drug claims, she said.
You may also be interested in...
Attorney Steven Shapiro, a partner at Ullman, Shapiro & Ullman, LLP, offers perspective on what he considers some of the biggest challenges cosmetics companies face in the current regulatory and legal landscape, specifically when it comes to crafting claims. Story features audio clips from the attorney’s interview with “The Rose Sheet.”
Yet another skin-care marketer, Skin Authority, has been served with an FDA warning letter for excessive product claims that identify its offerings as drugs. The agency cites statements touting the firm’s ingredient benefits, including collagen production, improved circulation, inflammation relief and hyperpigmentation treatment, consistent with other warnings issued to cosmetics firms in recent months.
Ronald Moy, a cosmetic surgeon practicing in Los Angeles and former president of the American Academy of Dermatology, receives an FDA warning letter for unapproved drug claims on his DNA Eye Renewal product, part of the doctor’s DNAEGF Renewal line marketed online. The warning, newly posted to FDA’s website, was one of three that went out to cosmetics players Feb. 12.